Monjazeb, A.M.; Wang, Z.; Vick, L.V.; Dunai, C.; Minnar, C.; Khuat, L.T.; Murphy, W.J.
Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers 2021, 13, 729.
https://doi.org/10.3390/cancers13040729
AMA Style
Monjazeb AM, Wang Z, Vick LV, Dunai C, Minnar C, Khuat LT, Murphy WJ.
Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers. 2021; 13(4):729.
https://doi.org/10.3390/cancers13040729
Chicago/Turabian Style
Monjazeb, Arta M., Ziming Wang, Logan V. Vick, Cordelia Dunai, Christine Minnar, Lam T. Khuat, and William J. Murphy.
2021. "Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms" Cancers 13, no. 4: 729.
https://doi.org/10.3390/cancers13040729
APA Style
Monjazeb, A. M., Wang, Z., Vick, L. V., Dunai, C., Minnar, C., Khuat, L. T., & Murphy, W. J.
(2021). Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers, 13(4), 729.
https://doi.org/10.3390/cancers13040729